Source:http://linkedlifedata.com/resource/pubmed/id/20606414
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2010-7-28
|
| pubmed:abstractText |
A high absolute lymphocyte count (ALC) at diagnosis is known as a surrogate marker of favorable prognosis in newly diagnosed multiple myeloma (MM). Recent studies showed tumor sensitization and enhanced cytotoxicity of bortezomib. We hypothesized that a high ALC before bortezomib treatment would contribute to tumor sensitization and activated cytotoxicity of bortezomib in relapsed MM. Ninety-seven relapsed MM patients who underwent bortezomib-dexamethasone (Vel-Dex) therapy were analyzed. Median follow-up duration was 21 months and median age was 61 years. Complete response (CR) and very good partial response (VGPR) after 2 cycles of Vel-Dex therapy were higher in the high-ALC group (>or=1.1 x 10(9)/l) (CR + VGPR 50.0% in the high-ALC group vs. 10.4% in the low-ALC group, p = 0.001), and stable disease (SD) rate was lower in the high-ALC group (SD 11.8% in the high-ALC group vs. 44.8% in the low-ALC group, p < 0.001). In the univariate analysis, the low-ALC group before therapy was associated with shorter progression-free survival (PFS) [hazard ratio (HR), 2.780; 95% confidence interval (95% CI) 1.703-4.536, p < 0.001]. Multivariate analysis revealed that a low ALC represented an independent predictive factor for PFS (HR 1.937, 95% CI 1.168-3.212, p = 0.010). A low ALC just before Vel-Dex therapy was associated with a poor prognosis in relapsed MM.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1421-9662
|
| pubmed:author |
pubmed-author:ChoGoon-JaeGJ,
pubmed-author:ChoiYoung-JinYJ,
pubmed-author:ChungJoo-SeopJS,
pubmed-author:JooYoung-DonYD,
pubmed-author:KimSeung-GeunSG,
pubmed-author:KimSung-HyunSH,
pubmed-author:LeeGyeong-WonGW,
pubmed-author:LeeHo-supHS,
pubmed-author:LeeSang-MinSM,
pubmed-author:SeolYoung-MiYM,
pubmed-author:ShinHo-JinHJ,
pubmed-author:SongMoo-KonMK,
pubmed-author:YunEun-YoungEY
|
| pubmed:copyrightInfo |
Copyright 2010 S. Karger AG, Basel.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
124
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
34-9
|
| pubmed:meshHeading |
pubmed-meshheading:20606414-Adult,
pubmed-meshheading:20606414-Aged,
pubmed-meshheading:20606414-Aged, 80 and over,
pubmed-meshheading:20606414-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20606414-Boronic Acids,
pubmed-meshheading:20606414-Dexamethasone,
pubmed-meshheading:20606414-Disease-Free Survival,
pubmed-meshheading:20606414-Female,
pubmed-meshheading:20606414-Humans,
pubmed-meshheading:20606414-Lymphocyte Count,
pubmed-meshheading:20606414-Lymphocytes,
pubmed-meshheading:20606414-Male,
pubmed-meshheading:20606414-Middle Aged,
pubmed-meshheading:20606414-Multiple Myeloma,
pubmed-meshheading:20606414-Predictive Value of Tests,
pubmed-meshheading:20606414-Prognosis,
pubmed-meshheading:20606414-Pyrazines,
pubmed-meshheading:20606414-Recurrence,
pubmed-meshheading:20606414-Remission Induction,
pubmed-meshheading:20606414-Salvage Therapy
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
|
| pubmed:affiliation |
Departments of Hematology-Oncology, Busan National Cancer Center, Pusan National University Hospital Medical Research Institute, Seo-gu, Busan, Republic of Korea.
|
| pubmed:publicationType |
Journal Article
|